That is, the K-Ras targeted therapy (with inhibitors), though can inhibit the cancer cell growth, may promote cancer stemness thus maintain CSCs and inflammation potential that will lead to tumor recurrence and metastasis. This evidence concerns the gene KRAS and neoplasm.